One possible treatment approach is glucagon-like peptide-1 (GLP-1) agonists, which mimic a natural hormone that suppresses appetite, regulates insulin and blood sugar and slows emptying of the stomach
if a clinician wants a central agent, PT-141 is likely the go-to
[44] has highlighted a significant genetic correlation (rg = 0.52, p = 6.4010 12 ) between OSA and T2D, indicating a possible shared genetic foundation for both conditions
NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death
Medication and clinical service fees are billed and collected by the practice-management platform that supports the prescribing clinicians
However, gastrointestinal side effectsparticularly nauseacan be pronounced, especially during dose escalation